Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, has told DirectorsTalk that Michael Sinclair, Executive Chairman of the Company, on 18 December 2015 purchased 500,000 ordinary shares of 1 penny each in the Company at 6.25 pence per Ordinary Share.
The Company also announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, on 18 December 2015 purchased 750,000 Ordinary Shares at 6.75 pence per Ordinary Share.
Following the above transactions, Michael Sinclair now holds 90,079,757 Ordinary Shares representing 6.35% of the issued share capital of the Company and Michael Bradfield now holds 124,518,510 Ordinary Shares representing 8.78% of the issued share capital of the Company.
